Have a feature idea you'd love to see implemented?
Let us know!
MDGL Madrigal Pharmaceuticals Inc
Price (delayed)
$329.24
Market cap
$7.18B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$25.12
Enterprise value
$7.06B
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone pathway in the liver, which is a key regulatory mechanism common to a spectrum
Highlights
The company's quick ratio has surged by 149% YoY but it fell by 32% QoQ
The company's net income fell by 49% YoY
The EPS has decreased by 31% YoY
Key stats
What are the main financial stats of MDGL
Market
Valuations
Earnings
Shares outstanding
21.81M
Market cap
$7.18B
Enterprise value
$7.06B
Price to earnings (P/E)
N/A
Price to book (P/B)
9.2
Price to sales (P/S)
93.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
91.94
Revenue
$76.81M
EBIT
-$503.53M
EBITDA
-$503.11M
Free cash flow
-$438.32M
Per share
Balance sheet
Liquidity
EPS
-$25.12
Free cash flow per share
-$20.16
Book value per share
$35.79
Revenue per share
$3.53
TBVPS
$49.13
Total assets
$1.07B
Total liabilities
$296.11M
Debt
$119.14M
Equity
$777.16M
Working capital
$885.82M
Debt to equity
0.15
Current ratio
5.98
Quick ratio
5.81
Net debt/EBITDA
0.24
Margins
Efficiency
Dividend
EBITDA margin
-655%
Gross margin
96.4%
Net margin
-675.2%
Operating margin
-713.5%
Return on assets
-53.3%
Return on equity
-71.8%
Return on invested capital
-85.4%
Return on capital employed
-56.2%
Return on sales
-655.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MDGL stock price
How has the Madrigal Pharmaceuticals stock price performed over time
Intraday
3.83%
1 week
8.78%
1 month
57.61%
1 year
74.72%
YTD
42.29%
QTD
55.14%
Financial performance
How have Madrigal Pharmaceuticals's revenue and profit performed over time
Revenue
$76.81M
Gross profit
$74.03M
Operating income
-$548.05M
Net income
-$518.67M
Gross margin
96.4%
Net margin
-675.2%
The net margin has surged by 81% since the previous quarter
Madrigal Pharmaceuticals's operating margin has soared by 80% from the previous quarter
MDGL's operating income has shrunk by 57% YoY and by 3.4% QoQ
The company's net income fell by 49% YoY
Growth
What is Madrigal Pharmaceuticals's growth rate over time
Valuation
What is Madrigal Pharmaceuticals stock price valuation
P/E
N/A
P/B
9.2
P/S
93.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
91.94
The EPS has decreased by 31% YoY
The stock's price to book (P/B) is 57% less than its 5-year quarterly average of 21.4 but 21% more than its last 4 quarters average of 7.6
The equity is down by 9% since the previous quarter
Efficiency
How efficient is Madrigal Pharmaceuticals business performance
The ROS has soared by 81% from the previous quarter
The ROE has soared by 76% YoY and by 25% from the previous quarter
Madrigal Pharmaceuticals's ROIC has soared by 63% YoY and by 23% from the previous quarter
MDGL's return on assets has surged by 53% year-on-year and by 20% since the previous quarter
Dividends
What is MDGL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MDGL.
Financial health
How did Madrigal Pharmaceuticals financials performed over time
The current ratio has surged by 153% year-on-year but it has declined by 31% since the previous quarter
The company's quick ratio has surged by 149% YoY but it fell by 32% QoQ
The debt is 85% smaller than the equity
Madrigal Pharmaceuticals's debt to equity has shrunk by 97% YoY but it has increased by 7% QoQ
The equity is down by 9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.